Ltd. Kck Sells 3,318 Shares of NeuroPace, Inc. (NASDAQ:NPCE) Stock

NeuroPace, Inc. (NASDAQ:NPCE) major shareholder Ltd. Kck sold 3,318 shares of the business’s stock in a transaction dated Thursday, October 3rd. The stock was sold at an average price of $6.97, for a total transaction of $23,126.46. Following the sale, the insider now directly owns 5,550,771 shares of the company’s stock, valued at $38,688,873.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ltd. Kck also recently made the following trade(s):

• On Wednesday, October 16th, Ltd. Kck sold 6,900 shares of NeuroPace stock. The stock was sold at an average price of $6.57, for a total value of $45,333.00.
• On Monday, October 14th, Ltd. Kck sold 4,031 shares of NeuroPace stock. The stock was sold at an average price of $6.54, for a total value of $26,362.74.
• On Friday, October 11th, Ltd. Kck sold 2,572 shares of NeuroPace stock. The shares were sold at an average price of $6.35, for a total value of $16,332.20.
• On Wednesday, October 9th, Ltd. Kck sold 3,123 shares of NeuroPace stock. The stock was sold at an average price of $6.10, for a total value of $19,050.30.
• On Monday, October 7th, Ltd. Kck sold 4,910 shares of NeuroPace stock. The shares were sold at an average price of $6.66, for a total value of $32,700.60.

NeuroPace Price Performance

NeuroPace stock opened at $6.47 on Friday. The company has a current ratio of 6.37, a quick ratio of 5.47 and a debt-to-equity ratio of 5.97. The company has a 50-day moving average price of $7.05 and a 200 day moving average price of $8.38. NeuroPace, Inc. has a 12-month low of $5.73 and a 12-month high of $18.15. The stock has a market cap of $186.13 million, a P/E ratio of -5.44 and a beta of 1.78.

NeuroPace (NASDAQ:NPCE) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. The business had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative net margin of 41.63% and a negative return on equity of 195.26%. The business’s revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.36) EPS. Sell-side analysts anticipate that NeuroPace, Inc. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NPCE has been the subject of a number of research reports. Wells Fargo & Company dropped their target price on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating for the company in a report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price objective on shares of NeuroPace in a research note on Wednesday, August 14th. Finally, Morgan Stanley decreased their target price on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.00.

Hedge Funds Weigh In On NeuroPace

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in NeuroPace by 18.3% in the first quarter. Vanguard Group Inc. now owns 488,618 shares of the company’s stock valued at $6,450,000 after buying an additional 75,512 shares during the last quarter. Hillsdale Investment Management Inc. acquired a new position in shares of NeuroPace in the 1st quarter worth approximately $155,000. Millennium Management LLC boosted its position in shares of NeuroPace by 13.3% during the 2nd quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after purchasing an additional 80,324 shares during the period. Acadian Asset Management LLC acquired a new stake in NeuroPace in the 1st quarter valued at approximately $621,000. Finally, Financial Advocates Investment Management increased its holdings in NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock valued at $113,000 after purchasing an additional 5,000 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.